Universal Biosensors Inc
ASX:UBI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
U
|
Universal Biosensors Inc
ASX:UBI
|
AU |
|
I
|
Inflection Point Acquisition Corp II
NASDAQ:IPXX
|
US |
|
Decisive Dividend Corp
XTSX:DE
|
CA |
|
C
|
Companhia Energetica do Rio Grande do Norte Cosern
BOVESPA:CSRN6
|
BR |
|
J
|
Jinzai Food Group Co Ltd
SZSE:003000
|
CN |
|
FM Mattsson AB (publ)
STO:FMM B
|
SE |
|
R
|
Rimon Consulting & Management Services Ltd
TASE:RMON
|
IL |
|
N
|
Nouveau Global Ventures Ltd
BSE:531465
|
IN |
|
S
|
Suzhou YourBest New-type Materials Co Ltd
SZSE:301266
|
CN |
|
Mind Technology Inc
NASDAQ:MIND
|
US |
Universal Biosensors Inc
Universal Biosensors, Inc. engages in the research, development and manufacture of medical diagnostics test systems for point-of-care professional and home use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2006-12-13. The firm is engaged in developing and commercializing a range of biosensors in oenology (wine industry), human health including oncology, coagulation, COVID-19, women’s health and fertility, non-human and environmental testing using its patented platform technology and hand-held point of use devices. Its core technology consists of a disposable, multi-layer test strip, which incorporates a proprietary electrochemical sensing system using opposing electrodes that detects specific analytes in samples as small as a droplet. Its products include Sentia, a wine analyzer, and Xprecia Prime, a coagulation analyzer. Its Hemostasis Reference Laboratory Meso Scale Discovery (MSD) multiplex platform couples immunoassay methodology with electrochemiluminescence (ECL) detection to provide measurement of a multitude of different cytokine panels. Its laboratory services include assay validation and analysis and consultation for study design.
Universal Biosensors, Inc. engages in the research, development and manufacture of medical diagnostics test systems for point-of-care professional and home use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2006-12-13. The firm is engaged in developing and commercializing a range of biosensors in oenology (wine industry), human health including oncology, coagulation, COVID-19, women’s health and fertility, non-human and environmental testing using its patented platform technology and hand-held point of use devices. Its core technology consists of a disposable, multi-layer test strip, which incorporates a proprietary electrochemical sensing system using opposing electrodes that detects specific analytes in samples as small as a droplet. Its products include Sentia, a wine analyzer, and Xprecia Prime, a coagulation analyzer. Its Hemostasis Reference Laboratory Meso Scale Discovery (MSD) multiplex platform couples immunoassay methodology with electrochemiluminescence (ECL) detection to provide measurement of a multitude of different cytokine panels. Its laboratory services include assay validation and analysis and consultation for study design.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
